PML
PML (PML nuclear body scaffold, also known as MYL, TRIM19 and RNF71) is a tripartite motif protein that organises PML nuclear bodies. It acts as a tumour suppressor and transcription factor, and contributes to antiviral defence. Browse Assay Genie's current range of PML research reagents below, or read on for the biology behind the target.
PML is best known as the scaffold of PML nuclear bodies (PML-NBs), nuclear structures in which it functions as a transcription factor and tumour suppressor. Its expression is cell-cycle related, and it regulates the p53 response to oncogenic signals. PML also exhibits antiviral activity against both DNA and RNA viruses. This activity can involve one or several isoforms and can be enhanced by the permanent PML-NB-associated protein DAXX or by the recruitment of p53/TP53 into these structures.
Individual isoforms act against different viruses. PML-4 restricts varicella zoster virus by sequestering virion capsids in PML-NBs, and, when sumoylated, restricts rabies virus by inhibiting viral mRNA and protein synthesis. The cytoplasmic isoform PML-14 restricts herpes simplex virus-1 by sequestering the viral E3 ligase ICP0 in the cytoplasm. PML-6 restricts human cytomegalovirus and influenza A strains, while PML-3 acts against poliovirus by recruiting and activating p53 in PML-NBs, and represses human foamy virus transcription by complexing its transactivator bel1/tas. PML also functions as an E3 SUMO-protein ligase that sumoylates the cytomegalovirus immediate early protein IE1; PML-3 and PML-6 show the highest sumoylation activity.
The PML gene encodes a member of the tripartite motif (TRIM) family, whose TRIM motif contains a RING domain, two zinc-binding B-boxes and a coiled-coil region. HGNC classes it among RING finger E3 ubiquitin protein ligases. The PML protein is a phosphoprotein found mainly in the nucleus, with further annotated locations including the nucleolus, cytoplasm, endoplasmic reticulum membrane and early endosome membrane. Extensive alternative splicing varies the central and C-terminal regions, while all variants share the same N-terminus. The gene is often involved in a translocation with the retinoic acid receptor alpha gene in acute promyelocytic leukaemia (APL), which gave rise to its former name, promyelocytic leukaemia.
The PML gene is often translocated with the retinoic acid receptor alpha gene in acute promyelocytic leukaemia, making it central to APL research.
PML regulates the p53 response to oncogenic signals and has cell-cycle-related expression, so it is studied in tumour suppressor pathways.
PML isoforms restrict a range of DNA and RNA viruses, including herpesviruses, rabies virus and influenza A, through PML nuclear bodies.
PML scaffolds nuclear bodies and acts as an E3 SUMO-protein ligase, supporting work on sumoylation and nuclear organisation.
PML scaffolds PML nuclear bodies, where it acts as a transcription factor and tumour suppressor and regulates the p53 response to oncogenic signals. It also restricts many DNA and RNA viruses and functions as an E3 SUMO-protein ligase.
PML is also called MYL, TRIM19 and RNF71, and was formerly named promyelocytic leukaemia. Extensive alternative splicing gives several isoforms, such as PML-3, PML-4, PML-6 and PML-14, which differ in central and C-terminal regions but share the same N-terminus.
The PML gene is often involved in a translocation with the retinoic acid receptor alpha gene in acute promyelocytic leukaemia. A mouse ortholog, Pml, is recorded. Check the datasheet of any product for its validated reactivity.
Tumour suppressors, SUMO pathway components, TRIM family proteins and nuclear body partners relevant to PML research.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P29590; product specifications from Assay Genie datasheets.